PMID- 1637784
OWN - NLM
STAT- MEDLINE
DCOM- 19920831
LR  - 20191028
IS  - 1053-8550 (Print)
IS  - 1053-8550 (Linking)
VI  - 12
IP  - 1
DP  - 1992 Jul
TI  - Human leukocyte antigen expression in renal cell carcinoma lesions does not 
      predict the response to interferon therapy.
PG  - 64-9
AB  - Human leukocyte antigen (HLA) classes I and II molecules are essential for 
      antigen presentation to cytotoxic T cells and helper T cells, respectively. 
      Consequently, they may play a role in anticancer immunotherapy as well. We 
      studied whether the pretreatment HLA phenotype of the tumor is predictive for 
      response to interferon immunotherapy in vivo. Therefore, renal cell carcinoma 
      (RCC) primary tumor lesions from 31 patients treated with interferon-alpha and 
      interferon-gamma (13 responders and 18 nonresponders) were analyzed 
      retrospectively for HLA antigen expression with immunohistochemical methods. 
      Furthermore, from eight patients, pretreatment metastatic lesions were examined. 
      In the primary tumors HLA class I expression was high: in 26 of 30 lesions more 
      than 50% cells were stained. HLA class II expression was mostly low: in 14 of 31 
      primary tumors less than 5% cells were stained. A significant correlation was 
      found between HLA phenotype of primary tumors and corresponding metastases. There 
      was no association between tumor HLA classes I and II antigen expression and 
      clinical response to interferon therapy. In conclusion, pretreatment HLA 
      phenotype of RCC has no predictive value for outcome of interferon immunotherapy. 
      A role for treatment-induced changes in HLA expression in vivo, however, can not 
      be excluded. These findings do not provide indications for the working mechanism 
      of interferon immunotherapy in vivo.
FAU - Mattijssen, V
AU  - Mattijssen V
AD  - Department of Medicine, University Hospital Nijmegen, The Netherlands.
FAU - Van Moorselaar, J
AU  - Van Moorselaar J
FAU - De Mulder, P H
AU  - De Mulder PH
FAU - Schalkwijk, L
AU  - Schalkwijk L
FAU - Ruiter, D J
AU  - Ruiter DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunother (1991)
JT  - Journal of immunotherapy : official journal of the Society for Biological Therapy
JID - 9102704
RN  - 0 (HLA Antigens)
RN  - 0 (Interferon Type I)
RN  - 0 (Recombinant Proteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Renal Cell/*immunology/pathology/secondary/therapy
MH  - Dendritic Cells/immunology
MH  - Female
MH  - HLA Antigens/*analysis
MH  - Humans
MH  - Immunohistochemistry
MH  - Interferon Type I/*therapeutic use
MH  - Interferon-gamma/*therapeutic use
MH  - Kidney Neoplasms/*immunology/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Recombinant Proteins
MH  - Retrospective Studies
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.1097/00002371-199207000-00008 [doi]
PST - ppublish
SO  - J Immunother (1991). 1992 Jul;12(1):64-9. doi: 10.1097/00002371-199207000-00008.